Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently ...

Presentation: First Report of Phase Ib/2a Study Evaluating Safety and Early Efficacy of TN-201, an Adeno-Associated Virus Serotype 9 Gene Replacement Therapy, in Adults with MYBPC3 -Associated ...

Kingdom Come: Deliverance II dropped two spots to third place, Steam Deck remained in fourth place, and the Advanced Access release of Avowed debuted in fifth place. The Steam charts are ordered ...

New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.

"Our target is to have something very similar to FSR 4's upscaler available on PS5 Pro for 2026 titles as the next evolution ...

Pension Fund Administrator (PFA), Access ARM Pensions Limited is leveraging digital technology solutions to deliver seamless ...

Diamond drilling below New Murchison Gold’s Crown Prince open pit has hit visible gold and raised the likelihood of a longer ...

Our Monster Hunter Wilds Melding Pot guide explains how to unlock melding and how to access more melding options in the ...

Q4 2024 Earnings Call Transcript March 5, 2025 Ocugen, Inc. reports earnings inline with expectations. Reported EPS is $-0.05 EPS, expectations were $-0.05. Operator: Good morning, and welcome to ...

Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP ...

Ocugen (NASDAQ: OCGN) Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET ...